High Growth Tech Stocks In Switzerland Featuring Basilea Pharmaceutica And Two More

The Swiss market recently exhibited a modest recovery, with the benchmark SMI index managing to edge slightly higher despite earlier losses, reflecting a cautious yet resilient sentiment among investors. In this environment, identifying high-growth tech stocks like Basilea Pharmaceutica becomes crucial as they may offer potential opportunities for those looking to navigate the complexities of fluctuating market conditions.

Top 10 High Growth Tech Companies In Switzerland

Name	Revenue Growth	Earnings Growth	Growth Rating
LEM Holding	8.69%	18.43%	★★★★☆☆
Santhera Pharmaceuticals Holding	24.55%	35.40%	★★★★★★
ALSO Holding	12.69%	24.49%	★★★★☆☆
Comet Holding	19.66%	47.84%	★★★★★☆
SoftwareONE Holding	8.59%	52.33%	★★★★★☆
Cicor Technologies	7.10%	27.73%	★★★★☆☆
Addex Therapeutics	26.51%	33.31%	★★★★★☆
Basilea Pharmaceutica	9.24%	33.25%	★★★★★☆
MCH Group	4.41%	100.62%	★★★★☆☆
Sensirion Holding	13.86%	102.68%	★★★★☆☆

Click here to see the full list of 12 stocks from our SIX Swiss Exchange High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Basilea Pharmaceutica (SWX:BSLN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company that develops products targeting medical needs in oncology and anti-infectives, with a market cap of CHF539.99 million.

Operations: The company generates revenue primarily from the discovery, development, and commercialization of innovative pharmaceutical products, amounting to CHF149.02 million. Its focus on oncology and anti-infectives forms the core of its business operations.

Despite being currently unprofitable, Basilea Pharmaceutica is on a trajectory to reverse its fortunes, with earnings expected to grow by an impressive 33.25% annually. This growth is anticipated as the company deepens its commitment to R&D, which is evident from its recent increase in guidance for 2024—expecting CHF 203 million in revenue and CHF 60 million in net profit. Furthermore, the extension of market exclusivity for Cresemba® until October 2027 following pediatric approval underscores Basilea's strategic focus on expanding and protecting its innovative drug portfolio. This forward-looking approach not only enhances potential revenue streams but also solidifies its standing in the high-stakes biotech sector.

• Take a closer look at Basilea Pharmaceutica's potential here in our health report.

• Review our historical performance report to gain insights into Basilea Pharmaceutica's's past performance.

Sensirion Holding (SWX:SENS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Sensirion Holding AG is a company that develops, produces, sells, and services sensor systems, modules, and components globally with a market capitalization of CHF1.10 billion.

Operations: The company generates revenue primarily from its sensor systems, modules, and components segment, amounting to CHF237.91 million.

Sensirion Holding, navigating through a challenging landscape marked by a recent shift from net income to a net loss of CHF 36.01 million, contrasts starkly with its previous year's profit. Despite this setback, the company is poised for recovery with projected revenue growth at 13.9% annually, outpacing the Swiss market's 4.3%. This optimism is bolstered by forecasts of an explosive annual earnings increase of 102.7%. Sensirion’s commitment to innovation is underscored by its significant investment in R&D, crucial for sustaining long-term competitiveness in the high-tech sensor market.

• Dive into the specifics of Sensirion Holding here with our thorough health report.

• Gain insights into Sensirion Holding's past trends and performance with our Past report.

Temenos (SWX:TEMN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Temenos AG specializes in developing, marketing, and selling integrated banking software systems to financial institutions globally, with a market cap of CHF 4.31 billion.

Operations: The company generates revenue primarily from two segments: Product, contributing $879.99 million, and Services, adding $132.98 million.

Temenos, amidst a transformative phase, recently bolstered its leadership with the appointment of Barb Morgan as Chief Product and Technology Officer. This strategic move underscores their commitment to integrating AI and cloud technologies, enhancing their offerings to financial institutions globally. With a 7.6% expected annual revenue growth outpacing the Swiss market's 4.3%, and an earnings projection surging by 14.4% annually, Temenos is poised for robust expansion. Their recent share buyback of CHF 200 million represents a substantial investment back into the company, signaling confidence in long-term value creation through innovation-focused strategies in software solutions for banking and finance sectors.

• Click here and access our complete health analysis report to understand the dynamics of Temenos.

• Assess Temenos' past performance with our detailed historical performance reports.

Make It Happen

• Reveal the 12 hidden gems among our SIX Swiss Exchange High Growth Tech and AI Stocks screener with a single click here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com